Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
46 hedge funds and large institutions have $62.4M invested in Allena Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 15 reducing their positions, and 12 closing their positions.
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
6% less funds holding
Funds holding: 49 → 46 (-3)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
46% less capital invested
Capital invested by funds: $116M → $62.4M (-$54M)
47% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.78M |
| 2 |
Renaissance Technologies
New York
|
+$335K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$328K |
| 4 |
Goldman Sachs
New York
|
+$318K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$285K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.68M |
| 2 |
BlackRock
New York
|
-$2.69M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.27M |
| 4 |
JP Morgan Chase
New York
|
-$941K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$292K |
ALNA Hedge Fund Activity: Q2 2019 in Review
46 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2019, worth a combined $62.4M — down 46% from $116M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ALNA and 11 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.78M. The largest seller was PFM Health Sciences, cutting an estimated $3.68M.
- 46 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2019, down from 49 in Q1 2019.
- Funds reported $62.4M of Allena Pharmaceuticals stock for Q2 2019, down 46% quarter-over-quarter.
- 11 funds opened new Allena Pharmaceuticals positions in Q2 2019 and 12 closed out, a net change of -1 holder.
- The largest Allena Pharmaceuticals buyer in Q2 2019 was Millennium Management, an estimated $1.78M added.
- The largest Allena Pharmaceuticals seller in Q2 2019 was PFM Health Sciences, an estimated $3.68M sold.
Based on aggregated 13F filings for Q2 2019.